GentiBio
presented preclinical data for GNTI-122, its autologous antigen-specific engineered Treg lead, an approach designed to restore tolerance with tissue-restricted specificity.
- Country
- United States
Antigen-specific Treg (GNTI-122)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Stem cell therapy for autoimmune disease | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.